The UAB Center for AIDS Research (CFAR) is a designated University-wide Center, a department-level status, and is concerned by a Constitution and By-Laws. The overall research goals of investigators in the UAB CFAR are to understand at the molecular level, and at the level of the infected individual, the pathogenesis of HIV infection and to utilize this information in conjunction with investigators pursuing experimental therapeutics, vaccine development, and behavioral modification to interfere with this pathogenic process. The multidisciplinary base of the Center ensures the rapid translation of fundamental knowledge about AIDS and its related disorders into these clinical treatment and prevention programs. In order to facilitate this process, the major objectives of the Center for AIDS Research are threefold. 1. To enhance ongoing outstanding research programs by facilitating interdisciplinary interactions, providing critical shared resource facilities, and providing administrative and fiscal management support mechanisms for Center investigators. 2. To stimulate participation of existing junior and established faculty in research programs aimed at AIDS-related subjects. This will be through the continued administration of a peer-reviewed competitive Developmental Grant Program that will provide funding for both developmental and pilot grants. 3. To stimulate recruitment and program developmental efforts in AIDS- related areas. The Center has identified new program areas and will assist Departments and Divisions in the process of investigator recruitment. Thus we anticipate continued growth and development of AIDS-related research in the CFAR. The Center will be led Dr. Eric Hunter (Director) and by an Executive Steering Committee consisting of Dr. George Shaw (Deputy Director) and seven Associate Directors, Drs. Beatrice Hahn (Basic Sciences and Program Development), Laura Leviton (Prevention Sciences), Jiri Mestecky (Vaccine Development), Michael Saag (Clinical Care and Experimental Therapeutics), John-Pierre Sommadossi (Pre-Clinical Therapeutics Development), Richard Whitley (Clinical Sciences) and Sten Vermund (Epidemiology). The Center is comprised of 120 Center members from 24 Divisions and Departments within the University funded by more than 100 AIDS-related grants and contracts totalling more than $35 million in research support. Eleven Core Facilities are proposed (Clinical, Biostatistics, Central Virus, Molecular Biology, DNA Sequence, Flow Cytometry, SCID-hu Mouse, International Research, and Behavioral Science, as well as Developmental and Administrative) that will provide key support for this funded research base. From its inception, the UAB CFAR has played a pivotal role in stimulating and supporting basic and clinical AIDS research and linking the two through interdisciplinary research programs. This has been most evident in the Center's principal thematic areas of viral pathogenesis, experimental therapeutics, and vaccine development. The success of the UAB CFAR is reflected in the growth in extramural funding for AIDS-related research from $4.0 million in 1988 (annual costs) to greater than $35.o million in 1997 (annual costs), the increase in number of R01-type AIDS-related grants from 5 to 50 during this same period, and the large number (>1,000) of AIDS-related publications by Center members in peer-reviewed scientific journals between 1993 and 1997. All of the major research efforts within the Center link basic and clinical/behavioral research and together they utilize every shared facility supported by the CFAR Core grant.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027767-13
Application #
6163863
Study Section
Special Emphasis Panel (ZAI1-SCO-A (J1))
Program Officer
Plaeger, Susan F
Project Start
1988-03-30
Project End
2003-02-28
Budget Start
2000-03-01
Budget End
2001-02-28
Support Year
13
Fiscal Year
2000
Total Cost
$1,470,407
Indirect Cost
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Tomalka, Amanda G; Resto-Garay, Ivelisse; Campbell, Kerry S et al. (2018) In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol 9:2552
Mai, Uyen; Mirarab, Siavash (2018) TreeShrink: fast and accurate detection of outlier long branches in collections of phylogenetic trees. BMC Genomics 19:272
AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord (2018) Non-Hodgkin lymphoma risk in adults living with HIV across five continents. AIDS 32:2777-2786
Ram, Daniel R; Manickam, Cordelia; Hueber, Brady et al. (2018) Tracking KLRC2 (NKG2C)+ memory-like NK cells in SIV+ and rhCMV+ rhesus macaques. PLoS Pathog 14:e1007104
Elion, Richard A; Althoff, Keri N; Zhang, Jinbing et al. (2018) Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. J Acquir Immune Defic Syndr 78:62-72
Rice, Whitney S; Logie, Carmen H; Napoles, Tessa M et al. (2018) Perceptions of intersectional stigma among diverse women living with HIV in the United States. Soc Sci Med 208:9-17
Stoll, Matthew L; Weiss, Pamela F; Weiss, Jennifer E et al. (2018) Age and fecal microbial strain-specific differences in patients with spondyloarthritis. Arthritis Res Ther 20:14
Fredericksen, R J; Gibbons, L; Brown, S et al. (2018) Medication understanding among patients living with multiple chronic conditions: Implications for patient-reported measures of adherence. Res Social Adm Pharm 14:540-544
Kay, Emma S; Rice, Whitney S; Crockett, Kaylee B et al. (2018) Experienced HIV-Related Stigma in Health Care and Community Settings: Mediated Associations With Psychosocial and Health Outcomes. J Acquir Immune Defic Syndr 77:257-263
Subramaniam, Akila; Van Der Pol, William J; Ptacek, Travis et al. (2018) Midtrimester microbial DNA variations in maternal serum of women who experience spontaneous preterm birth. J Matern Fetal Neonatal Med :1-9

Showing the most recent 10 out of 955 publications